Abstract
Objective: The mechanisms by which bariatric surgeries, including gastric bypass (GB) and sleeve gastrectomy (SG), achieve remission of type 2 diabetes mellitus (T2DM) and sustained weight reduction are unknown. We hypothesized that the novel anorexic hormone nesfatin-1 and another new hormone obestatin might contribute to the marked improvement in glycemic homeostasis and weight loss in diabetics after GB and SG.
Methods: A hospital-based, prospective study was conducted. Overnight fasting plasma concentrations of nesfatin-1 and obestatin were analyzed in T2DM patients before surgery, and at 3 and 12 months after laparoscopic GB (n =12) and SG (n = 6).
Results: At 12 months, reductions of body mass index (BMI), fasting blood glucose, and glycated hemoglobin were similar between GB and SG groups (P all > 0.05). Plasma nesfatin-1 levels in patients undergoing GB or SG significantly decreased after surgeries (P both < 0.05). In contrast, plasma obestatin concentrations significantly increased in patients after SG (P < 0.05) but without any alteration after GB. The alterations of plasma nesfatin-1 were significantly and negatively associated with the reduction of fasting blood glucose (P < 0.05) at 12 months after GB and SG. In the SG group, the reduction of nesfatin-1 significantly and positively correlated with the decrease of BMI (P < 0.05).
Conclusions: GB and SG produce differential influences with regards to circulating nesfatin-1 and obestatin levels in non-morbidly obese, T2DM patients. Circulating nesfatin-1 may modulate glucose homeostasis in two surgical procedures, and participate in regulating body weight in SG.
Keywords: Bariatric surgery, diabetes mellitus, gastric bypass, nesfatin-1, obestatin, sleeve gastrectomy.
Current Pharmaceutical Design
Title:Differential Influences of Gastric Bypass and Sleeve Gastrectomy on Plasma Nesfatin-1 and Obestatin Levels in Patients with Type 2 Diabetes Mellitus
Volume: 19 Issue: 32
Author(s): Wei-Jei Lee, Chih-Yen Chen, Kong-Han Ser, Keong Chong, Shu-Chun Chen, Pui-Ching Lee, You-Di Liao and Shou-Dong Lee
Affiliation:
Keywords: Bariatric surgery, diabetes mellitus, gastric bypass, nesfatin-1, obestatin, sleeve gastrectomy.
Abstract: Objective: The mechanisms by which bariatric surgeries, including gastric bypass (GB) and sleeve gastrectomy (SG), achieve remission of type 2 diabetes mellitus (T2DM) and sustained weight reduction are unknown. We hypothesized that the novel anorexic hormone nesfatin-1 and another new hormone obestatin might contribute to the marked improvement in glycemic homeostasis and weight loss in diabetics after GB and SG.
Methods: A hospital-based, prospective study was conducted. Overnight fasting plasma concentrations of nesfatin-1 and obestatin were analyzed in T2DM patients before surgery, and at 3 and 12 months after laparoscopic GB (n =12) and SG (n = 6).
Results: At 12 months, reductions of body mass index (BMI), fasting blood glucose, and glycated hemoglobin were similar between GB and SG groups (P all > 0.05). Plasma nesfatin-1 levels in patients undergoing GB or SG significantly decreased after surgeries (P both < 0.05). In contrast, plasma obestatin concentrations significantly increased in patients after SG (P < 0.05) but without any alteration after GB. The alterations of plasma nesfatin-1 were significantly and negatively associated with the reduction of fasting blood glucose (P < 0.05) at 12 months after GB and SG. In the SG group, the reduction of nesfatin-1 significantly and positively correlated with the decrease of BMI (P < 0.05).
Conclusions: GB and SG produce differential influences with regards to circulating nesfatin-1 and obestatin levels in non-morbidly obese, T2DM patients. Circulating nesfatin-1 may modulate glucose homeostasis in two surgical procedures, and participate in regulating body weight in SG.
Export Options
About this article
Cite this article as:
Lee Wei-Jei, Chen Chih-Yen, Ser Kong-Han, Chong Keong, Chen Shu-Chun, Lee Pui-Ching, Liao You-Di and Lee Shou-Dong, Differential Influences of Gastric Bypass and Sleeve Gastrectomy on Plasma Nesfatin-1 and Obestatin Levels in Patients with Type 2 Diabetes Mellitus, Current Pharmaceutical Design 2013; 19 (32) . https://dx.doi.org/10.2174/13816128113198880010
DOI https://dx.doi.org/10.2174/13816128113198880010 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cerebral Artery Signal Transduction Mechanisms: Developmental Changes in Dynamics and Ca<sup>2+</sup> Sensitivity
Current Vascular Pharmacology Mechanisms Involved in Glycemic Control Promoted by Exercise in Diabetics
Current Diabetes Reviews Serum Hepcidin, the Hepcidin/Ferritin Ratio and the Risk of Type 2 Diabetes: A Systematic Review and Meta-Analysis
Current Medicinal Chemistry Statins and Vulnerable Plaque
Current Pharmaceutical Design Benefits of Resistance Training in Older Adults
Current Aging Science Family History of Type 2 Diabetes: Does Having a Diabetic Parent Increase the Risk?
Current Diabetes Reviews Genomics and the Prospects of Existing and Emerging Therapeutics for Cardiovascular Diseases
Current Pharmaceutical Design Old But Good: Modified-Release Prednisone in Rheumatoid Arthritis
Reviews on Recent Clinical Trials T-Lymphocytes: A Target for Stimulatory and Inhibitory Effects of Zinc Ions
Endocrine, Metabolic & Immune Disorders - Drug Targets BELFAST Centenarians: A Case of Optimal Cardiovascular Risk?
Current Pharmaceutical Design Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Pathogenesis and Treatment Options
Current Vascular Pharmacology Histone Deacetylase Inhibitors Target Diabetes via Chromatin Remodeling or as Chemical Chaperones?
Current Diabetes Reviews Anemia and Chronic Kidney Disease: Making Sense of the Recent Trials
Reviews on Recent Clinical Trials Neuron-glia Interaction as a Possible Pathophysiological Mechanism of Bipolar Disorder
Current Neuropharmacology CCR1 and CCR2 Antagonists
Current Topics in Medicinal Chemistry Peptide and Non-peptide Antagonists Targeting Endothelin Receptors in Physiology and Pathology
Current Pharmaceutical Design Involvement of Membrane Channels in Autoimmune Disorders
Current Pharmaceutical Design Treatment Strategies Against Diabetic Foot Ulcer: Success so Far and the Road Ahead
Current Diabetes Reviews Translating the Potential of Stem Cells for Diabetes Mellitus: Challenges and Opportunities
Current Stem Cell Research & Therapy Polymorphisms of the Aldose Reductase Gene and Susceptibility to Diabetic Microvascular Complications
Current Medicinal Chemistry